New York, New York--(Newsfile Corp. - October 6, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL) on behalf of investors that purchased or otherwise acquired Anavex securities between November 26, 2025 and August 28, 2026 (the "Class Period").

CLICK HERE TO JOIN THE CASE

If you are an investor in Anavex and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than November 30, 2026 for an opportunity to be lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

On May 11, 2026, according to the complaint, the Company filed a notification of late filing with the SEC and disclosed that it had "terminated the employment of Dr. Christopher Missling as the Chief Executive Officer of the Company on April 30, 2026 for, among other things, conduct that the Special Committee believed was inconsistent with Company Policy." On this news, Anavex stock fell $0.18 per share, or 5.55%, to close at $3.06 on May 12, 2026.

Then, on August 28, 2026, according to the complaint, Anavex filed an Amended 2025 Annual Report with the SEC. The report stated, in part, that as a result of a review by the Special Committee, management, in consultation with the Audit Committee of the Board, "concluded that there was a material weakness in internal control over financial reporting that existed at September 30, 2025" and that "the Company's disclosure controls and procedures were not effective." On this news, Anavex stock fell $0.19 per share, or 6.35%, to close at $2.80 on August 31, 2026, thereby injuring investors further.

The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that Anavex lacked adequate internal controls and that Anavex understated its potential regulatory challenges as a result of misconduct by former CEO Christopher Missling.

CLICK HERE TO LEARN MORE

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this Notice, your rights, or your interests, please contact:

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

https://www.kaplanfox.com/case/anavex-life-sciences-avxl-class-action/

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/317729

Source: Kaplan Fox & Kilsheimer LLP